Clinical Study of Wumei Pill on Hp Positive Atrophic Gastritis
Objective:To explore the therapeutic effect of Wumei Pill on patients with Helicobacter pylori(Hp)positive atrophic gastritis.Methods:A total of 100 patients with Hp positive atrophic gastritis who were treated in Foshan Traditional Chinese Medicine Hospital from January to December 2022 were selected,and divided into the treatment group(50 cases)and the control group(50 cases)by random number table method.The control group was given quadruple Hp eradication therapy,and the treatment group was given Wumei Pill combined with quadruple Hp eradication therapy.The Hp conversion rate,clinical efficacy,traditional chinese medicine syndrome score,gastroscopy and pathological conditions,as well as the levels of pepsinogen Ⅰ(PGⅠ)and pepsinogen Ⅱ(PGⅡ)of the two groups were compared.Results:In comparision of the control group(82.00%),the Hp conversion rate of the treatment group(96.00%)was higher(P＜0.05).In comparision of the control group(76.00%),the total effective rate of the treatment group(92.00%)was higher(P＜0.05).After treatment,the traditional chinese medicine syndrome score in both groups were decreased(P＜0.05),and in comparision of the control group,the treatment group was lower(P＜0.05).After treatment,the scores of gastroscopy and pathological conditions in both groups were decreased(P＜0.05),but there was no statistically significant difference between the two groups(P＞0.05).After treatment,the levels of PGⅠand PGⅡin both groups were increased(P＜0.05),and in comparision of the control group,the treatment group was higher(P＜0.05).Conclusion:The application of Wumei Pill in patients with Hp positive atrophic gastritis can promote Hp negative condition,improve clinical symptoms,enhance clinical efficacy,improve gastric mucosal atrophy,and increase PGⅠand PGⅡlevels.
万方数据
维普
